Clinical trial · Observational
Early Imaging Biomarkers in NSCLC
Early Imaging Biomarkers to Predict Radiation-Induced Cardiopulmonary Toxicity in Patients With Thoracic Malignancies
NCT03121287CI-TRIAL-00040227completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate if cardiac MRI, blood biomarkers, and lung CT scans can detect early changes to the associated with radiation therapy in patients receiving radiation treatment for thoracic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thoracic Cancer | Malignant Thoracic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imaging | Other | — | UNRESOLVED |
| Imaging Biomarkers | Other | — | UNRESOLVED |
| Pulmonary | Other | — | UNRESOLVED |
| Specimen Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lung or Esophageal Patients
- description
- Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test \& 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
- interventionNames
- Other: Imaging Biomarkers
- Other: Pulmonary
- Other: Imaging
- Other: Specimen Collection
Primary outcomes (1)
- measure
- Change from Baseline in Lung Function
- timeFrame
- 1 Year post treatment
- description
- To characterize longitudinal changes in lung function using a voxel-wise image analysis technique of whole-lung CT scans in patients undergoing intrathoracic radiation therapy.
Secondary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients receiving once daily fractionated intrathoracic radiation therapy for: * Stage IIA-IIIB non-small cell lung cancer * Limited stage small cell lung cancer * Stage I-III esophageal cancer (neoadjuvant or definitive) * Patients must be 18 years of age or older * Must not be claustrophobic * Must have adequate kidney function Exclusion Criteria: * Patients with small cell lung cancer receiving twice daily (b.i.d.) radiation * Patients with esophageal cancer receiving trastuzamab * Pregnancy or lactation * Claustrophobia * Inability to lie flat for 60-90 minutes * Renal dysfunction with eGFR \<60 mL/min/1.73 m2 * Allergy to gadolinium containing contrast media * Implanted devices, metallic hazards or other conditions presenting a contraindication to 3Tesla cardiac MRI
References
Publications (0)
Data not yet available
No reference posted for this study.